MENU
IHE
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IHE stock forecast, quote, news & analysis

The investment seeks to track the investment results of the Dow Jones U... Show more

Category: #Health
A.I.Advisor
published price charts
IHE
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for IHE with price predictions
Oct 19, 2026

IHE in downward trend: 10-day moving average moved below 50-day moving average on September 16, 2026

The 10-day moving average for IHE crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 70 cases where IHE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.

IHE moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

The Aroon Indicator for IHE entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IHE's RSI Indicator exited the oversold zone, 22 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on IHE as a result. In 64 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for IHE just turned positive on October 15, 2026. Looking at past instances where IHE's MACD turned positive, the stock continued to rise in 40 of 52 cases over the following month. The odds of a continued upward trend are 77%.

Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in 287 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

IHE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares U.S. Pharmaceuticals ETF (IHE) ETF is 57.65B. The market cap for tickers in the group ranges from 37.93M to 1.11T. LLY holds the highest valuation in this group at 1.11T. The lowest valued company is EYPT at 37.93M.

High and low price notable news

The average weekly price growth across all stocks in the iShares U.S. Pharmaceuticals ETF (IHE) ETF was 35%. For the same ETF, the average monthly price growth was 47%, and the average quarterly price growth was 157%. LQDA experienced the highest price growth at 23%, while EYPT experienced the biggest fall at -87%.

Volume

The average weekly volume growth across all stocks in the iShares U.S. Pharmaceuticals ETF (IHE) ETF was 52%. For the same stocks of the ETF, the average monthly volume growth was -43% and the average quarterly volume growth was 21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 51
Price Growth Rating: 48
SMR Rating: 73
Profit Risk Rating: 69
Seasonality Score: 27 (-100 ... +100)
IHE in downward trend: 10-day moving average moved below 50-day moving average on September 16, 2026